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January 2012304 AbstractsLong-Term Outcomes of Endovascular Intervention for May-Thurner
Syndrome
E.S. Hager1, R. Tahara2, E. Dillavou1, G. Al-Khoury1, T. Yuo1, R. Rhee1,
L. Marone1, M. Makaroun1, R.A. Chaer1, 1University of Pittsburgh Med-
ical Center, Pittsburgh, Pa, 2Bradford Regional Medical Center, Bradford,
Pa
Background: Endovascular interventions for May Thurner Syndrome
(MTS) have become first line therapy, often performed in a young patient
population despite the lack of robust supportive data. This paper reports on
long term outcomes from a large series of patients treated for de-novo or
posthrombotic presentation.
Methods: A retrospective review of MTS patients stented between
2006 and 2010 at two institutions. Patients who presented with acute
iliofemoral DVT were treated with either catheter directed thrombolysis
(CDT) and/or pharmacomechanical thrombolysis (PMT) and identified as
having a venous stenosis by venogram. Patients who presented with leg pain
or swelling but no DVT and evidence of MTS on duplex were evaluated by
venography. IVUS was selectively utilized. Stenting of the iliocaval junction
was performed in all patients with a50% diameter stenosis on venogram, or
a 70% area stenosis on IVUS.
Table. Patient characteristics and procedure analysis
Stenting after PMT/CDT
(postthrombotic) N38(%)
Stenting alone (de novo
presentation) N15(%) P value
Females 23 (61%) 11 (73%) .38
Average age 52 (range, 16-80 years) 55 (range, 25-67 years) .60
Hypercoagulable state 9 (24%) 0 .04
Coronary artery
disease
6 (16%) 1 (7%) .38
Diabetes 4 (11%) 4 (27%) .14
Hyperlipidemia 13 (34%) 3 (20%) .31
Hypertension 17 (45%) 7 (47%) .90
Left side 34 (89%) 11 (73%) .14
Average preoperative
CEAP score
2.7 3.8 .05
Number of patients
wearing
compression
stockings pre-
operatively
16 (42%) 15 (100%) .01
Average stent size
(mm)
14 mm (range, 10-22) 17 mm (range, 12-22) .01
IVUS use 19 (51%) 12 (80%) .04
Stent type .01
-Balloon expandable 7 (18%) 8 (53%)
-Self expanding 31 (82%) 7 (47%)
ŒProtégé (EV3) 28 (90%) 4 (57%)
ŒWallstent (Boston
Sci)
3 (10%) 3 (43%)
Bleeding
complications
0 0 N/A
Mean length of
follow-up
15 months 11 months
Complete or partial
symptom relief
31 (89%) 15 (100%) .17
Change in CEAP
score at follow-up
0.16 (P.81) 0.27 (P.04)
Results: 51 patients with MTS underwent 53 lower extremity inter-
ventions. They were divided into two groups: postthrombotic (Group 1)
and de-novo presentation of swelling/pain but no DVT (group 2). There
were 38 extremities in group 1 and 15 extremities in group 2 (Table). Both
groups were comparable in terms of gender distribution and comorbidities,
but hypercoagulable state was more common in group 1 (P.04), and
average CEAP score on presentation was higher in group 2 (P.05).There
were left sided symptoms in 34 (89%) patients in group 1 and 10 (77%) of
group 2 (P.26). Males represent 75% of patients with right sided symp-
toms, but only 30% of patients with left sided symptoms (P.019). The
average stent size was significantly different among the groups, (P.001),
with different types used in each group. (Table). There were no procedural
complications in either group. Mean follow-up was 15 months in group 1
(range, 1-42 months) and 11 months in group 2 (1-24 months). Complete
or partial symptom relief was reported for 31 (89%) extremities in group 1
and 15 (100%) extremities in group 2 (P.17). A normal Valsalva response
was seen in all patients with a patent stent on the most recent follow up
duplex, with an overall primary patency at 3 years by lifetable analysis of 96%
(94% in group1, 100% in group 2) and secondary patency of 98%.
a
WConclusion: Stenting of MTS has proven to be safe, efficacious and
urable for up to 36 months in both the post thrombotic patient as well as
hose treated for edema alone.
utcomes and Predictors of Secondary Intervention for Chronic Ve-
ous Insufficiency Following Endovenous Radiofrequency Ablation
.R. Diamond, M.S. Hong, D. Shelpman, P.R. Nelson, University of
lorida College of Medicine, Gainesville, Fla
Background: Endovenous ablation for the treatment of chronic venous
nsufficiency (CVI) affords patients aminimally invasive treatment alternative to
raditional surgical procedures. Endovenous ablation is highly technically and
linically successful such that only aminority of patientsmay require subsequent
reatment for either extensive varicosities or for veins in which ablation was
nsuccessful. The purpose of this study was to develop a predictive model to
orecast this requirement for secondary procedures despite successful primary
ndovenous radiofrequency ablation (RFA) for CVI.
Methods: Subjects were identified from a University Vein Center
atabase and assigned to one of two groups: (1) Control: patients whose
FA was successful as a primary standalone procedure in alleviating symp-
oms and decompressing varicosities, or (2) Reintervention: patients who
equired additional treatment to correct their disease after initial RFA did
ot provide a complete clinical response. For patients who had bilateral RFA,
ach limb was identified independently for both the primary and secondary
rocedures. Secondary procedures were defined as phlebectomy, vein strip-
ing, sapheno-femoral junction (SFJ) ligation, or radiofrequency ablation of
he same vein or additional accessory veins. Patients who were treated
xclusively with sclerotherapy as a secondary intervention were excluded.
ata was analyzed using sequential univariate and multivariate regressions
long with Chi-square goodness of fit.
Results: Of the 185 patients included in this study, 32 patients
equired a secondary intervention (17.3%). Secondary procedures included
hlebectomy 53%, secondary RFA 28%, combined RFA and phlebectomy
%, SFJ ligation 6%, and vein stripping 3%. The mean Venous Clinical
everity Scores (VCSS) for the control and reintervention groups were 4.8
nd 6.7, respectively (P.001). The overall median VCSS was 5 (range, 2 -
7). For subjects with a VCSS  5, the requirement for secondary proce-
ures was 10-fold greater. Univariate regression suggested that BMI, dia-
etes, pain, varicosities, edema, pigmentation, induration, compression, and
otal VCSS contributed to the need for secondary intervention at the p.1
evel. Multivariate regression modeling these covariates showed indepen-
ent predictive association between increasing total VCSS and secondary
ntervention (P.0001), and an inverse association between increasing BMI
nd a decreased risk of reintervention following RFA (P.008).
Conclusions: Secondary procedures were required only in 17% of
atients following RFA, so for most, a staged approach to any secondary
rocedures may be appropriate. With the knowledge gained from this study,
linicians may be able to better individualize patient treatment by identifying
hose at up front greater risk of requiring a secondary procedure. For this
ubset, providing comprehensive treatment, such as a combination of RFA
ith SFJ ligation or phlebectomy, could mitigate the risks of additional
urgical procedures.
oluble P-Selectin for the Diagnosis of Lower Extremity Deep Venous
hrombosis
.C. Vandy1, C. Stabler1, A.E. Hawley1, N. Ballard-Lipka1, K.E. Guire2,
. Baker1, D.D. Myers1, J.E. Rectenwald1, P.K. Henke1,
.W. Wakefield1, 1University of Michigan, Ann Arbor, Mich, 2Department
f Biostatistics, School of Public Health, University of Michigan, Ann
rbor, Mich
Background: Although duplex ultrasound is the gold standard for the
iagnosis of lower extremity deep venous thrombosis(LE-DVT), imaging is
ot always available. The use of D-dimer can exclude(high sensitivity), but
ot rule in(low specificity) LE-DVT. In a derivation cohort, we previously
emonstrated that soluble P-selectin(sPsel) with Wells score, establishes the
iagnosis of LE-DVT with specificity of 96% and positive predictive val-
e(PPV) of 100%. In order to validate our previous results, we applied the
odel from our derivation cohort to a separate but similar validation cohort,
iffering by allowing inclusion of patients on immunosuppression or pro-
hylactic anticoagulation.
Methods: Demographics, clinical data, D-dimer, sPsel, C-reactive
rotein(CRP), ADAMTS-13, and von Willebrand factor(vWF) levels were
rospectively collected in 160 patients presenting to our ultrasound lab with
n anticipated diagnosis of LE-DVT. Continuous (Students t-test) and
ategorical (Chi squared test) variables among patients with ultrasound
onfirmed LE-DVT were compared to patients without LE-DVT. The
iagnostic sensitivity, specificity, PPV and negative predictive value(NPV)
as then calculated using cut points from our derivation cohort to rule in
E-DVT (sPsel 90ng/mL or D-dimer 500ng/mL and Wells score2)
s well as exclude LE-DVT(sPsel60ng/mL or D-dimer500ng/mL and
ells score 2).
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Volume 55, Number 1 Abstracts 305Results: 80/160 patients had a confirmed LE-DVT. There was a
significant difference in all biomarkers among those patients with LE-DVT.
(Table I) When Wells score 2, sPsel could rule LE-DVT with a specificity
of 96% and a PPV of 89%, which was more accurate thanWells score2 and
D-dimer (specificity 65% and PPV 71%). (Table II) When Well’s score was
2, D-dimer was superior to sPsel for excluding the diagnosis of LE-DVT
(sensitivity 100%, NPV 100% vs. sensitivity 90%, NPV 77%). The use of
additional biomarkers did not increase the specificity/sensitivity for diagnos-
ing LE-DVT. Using a combination of Wells score, D-dimer, and sPsel we
could correctly diagnose LE-DVT in 27% (43/160) of patients without the
use of imaging.
Conclusions: In validating our previous study, we have demonstrated,
in the setting of Wells score 2, sPsel is an excellent biomarker rule in
LE-DVT. Different from our derivation cohort, D-dimer and a Wells score
2 was more sensitive at excluding a diagnosis of LEDVT than sPsel and a
Wells score 2. Together, Wells score, sPsel, and D-dimer can both rule in
and exclude LE-DVT.
Table I. Demographics and biomarkers
Variable
Negative LEDVT (95%
confidence intervals)
Positive LEDVT (95% confidence
intervals) P value
Female gender n
(%) 53 (66%) 34 (43%) .002
Age 53.2 years (50.2-56.1) 57.6 years (54.4-60.7) .046
Wells score 1.6 (1.4-1.8) 3.0 (2.6-3.3) .001
D-Dimer (ng/mL) 986.4 ng/mL (756.5-1216.3) 6268.4 ng/mL (5356.1-7180.7) .001
sPsel (ng/mL) 57.2 ng/mL (50.8-63.6) 78.4 ng/mL (70.8-85.9) .001
CRP (	g/mL) 1.34 	g/mL (0.65-2.03) 5.74 	g/mL (4.22-7.25) .001
vWF (% activity) 113.3% (95.3-131.3) 151.7% (134.6-168.8) .002
ADAMTS-13 (%
activity) 102% (97-106) 91% (86-95) .001
Table II. Specificity, sensitivity, positive predictive value, negative predictive value
Biomarker
Specificity (95%
confidence
interval)
Sensitivity (95%
confidence interval)
Positive
predictive
value
Negative
predictive
value
sPsel ( 90ng/mL) 
Wells score ( 2) 96% (88.7-99%) 31% (21.6-42.7%) 89% 58%
D-dimer ( 500ng/
mL) Wells score
(  2) 65% (53.4-75.1%) 84% (73.4-90.7%) 71% 80%
sPsel (60ng/mL) 
Wells score (2) 34% (23.8-45.3%) 90% (80.7-95.3) 58% 77%
D-dimer (500ng/
mL) Wells score
(2) 32% (22.7-44%) 100% (94.3-100%) 60% 100%
Deep Venous Thrombosis After Abdominal Aneurysm Repair
E. Xenos, D. Davenport, University of Kentucky Medical Center, Lexing-
ton, Ky
Objective: Thromboprophylaxis guidelines after abdominal aortic an-
eurysm repair are scarce. The objective of this study was to examine venous
thromboembolism (VTE) rates, timing and risk factors after nonruptured
open or endoluminal (ELG) Abdominal Aortic Aneurysm repair.
Methods: A systematic study of patients undergoing AAA repair was
performed. We queried the ACS NSQIP dataset from 2005-2009 for AAA
repairs using [CPT] and [ICD-9] codes. We excluded emergent/ruptured
AAA operations. Forward stepwise multivariable logistic regression of all
30-day VTE was performed.
Results:Our query yielded 12,469 patients. The mean age was 73.2
8.7 (s.d.) years and 2466 (19.8%) were female. The DVT rate within 30 days
of operation was 0.9% (n106) and the PE rate was 0.3% (n36). Diagnosis
of both was rare (n7) and the combined DVT or PE rate (VTE) was 1.1%
(n135). Thirty-day mortality was 1.9% (238/12,469) and VTE was asso-
ciated with increased 30-day mortality from 1.9% (232/12,102) in patients
without VTE to 4.4% (6/135) in patients with VTE (Chi-square p .035).
Thirty-percent (40/135) of treated VTEs were diagnosed after surgical
discharge. The median postoperative days to VTE diagnosis was 8 (inter-
quartile range, 4 to 15 days). Multivariable forward stepwise logistic regres-
sion yielded only four independent ACS NSQIP preoperative predictors of
VTE. They are shown in Table I by their order of entry into the model (and
therefore importance). This is after consideration of over fifty clinical risk
variables. Intraoperative risk factors are shown in Table II. After adjustment,
open repair had higher risk for VTE (OR, 1.46; 95% CI, 0.93-2.30) but this
was no longer statistically significant, p  .104.Risk factors identified were ASA class 4-5(odds ratio[OR] 1.77,
P.002), operative duration4hrs(OR 2.33, P.14) and intraoperative
i
mlood transfusion. Operative duration and transfusion were both risk factors
nd increased with increasing “dose”.
Discussion: Although VTE after AAA repair was infrequent, it was
ssociated with higher mortality. Open AAA repair increases risk for post-
perative VTE as compared to ELG. It was surprising to find that 1/3 of
TE’s were diagnosed after discharge. Patients with the aforementioned risk
actors may benefit from pharmacologic thromboprophylaxis after AAA
epair. Pharmacologic thromboprophylaxis may not be necessary after ELG.
able I.
tep Variable Incidence %
Odds ratio
(95% CI)
P
value
1 ASA class 4-5 vs
1-3
2480 19.9 1.77 (1.22-2.55) .002
2 Dyspnea 3049 24.5 1.68 (1.17-2.39) .005
3 Race vs white 10696 85.8 Reference
Black 467 3.7 2.21 (1.18-4.15) .013
Other/unknown 1306 10.5 0.93 (0.51-1.70) .820
4 Recent weight
loss  10%
2318 18.6 2.31 (1.00-5.32) .050
able II.
ariable Incidence %
Odds ratio for
VTE (95% C.I.)
P
value
pen vs endovascular
repair 3967 31.8 1.46 (0.93-2.30) .104
ntraoperative
transfusion PRBCs
vs none 8551 68.6 Reference
-2 U 2200 17.6 1.23 (0.73-2.08) .430
-4 U 978 7.8 1.48 (0.79-2.79) .221
 U 740 5.9 2.39 (1.27-4.48) .007
perative duration vs
 2 hrs 3133 25.1 Reference
.01-3 hrs 4350 34.9 1.78 (0.95-3.28) .070
.01-4 hrs 2586 20.7 1.70 (0.87-3.35) .123
4 hrs 2400 19.2 2.33 (1.18-4.59) .014
ound class not clean 320 2.6 2.01 (1.03-3.94) .041
hrombolytic Therapy For Significant Pulmonary Emboli
. Purdy1, H. Mckeever2, T. Khoury3, 1Shawnee State University, Ports-
outh, Ohio, 2Ohio University College of Osteopathic Medicine, Athens,
hio, 3Southern Ohio Surgical Associates, Portsmouth, Ohio
Background: This study is a retrospective review of the treatment of
atients with significant pulmonary emboli (PE) with thrombolytic therapy
n a rural setting hospital. Significant PE is defined as a patient with
ypoxemia  right ventricular strain  hemodynamic compromise. Long-
erm studies with emphasis on recurrent deep vein thrombosis was assessed
s well. Patients studied were in the interval of 2000-2010. Records prior to
000 were not available.
Methods: To review initial thrombolytic therapy, operative reports
ere interpreted and evaluated to determine therapy implemented, and if
omplete or partial lysis of emboli was achieved. For long-term studies
nnual venous duplexes were assessed.
Results: Records from 2000-2010 showed that 51 patients were
reated with thrombolytic therapy. Of those patients, 7 received Urokinase
drip ranges between 100,000 - 200,000 units/hour), 44 received TPA
drip ranges between 0.5 - 2 mg/hour). The majority of patients were
ripped via the Unifuse catheter; recently the EKOS catheter has been
mplemented upon which 9 out of 51 patients received. Thirty-five out of 51
atients received vena cava filters. Three patients received mechanical lysis
ith the Angiojet Device. All patients were on a heparin drip protocol
ystematically while on lytic therapy. The average drip duration for treatment
anged between 12 hours and 24 hours. The average drip duration for TPA
as 24.23 hours for bilateral treatment with a standard deviation of 21.68
ours. The average for Urokinase was 16.57 hours with a standard deviation
f  4.47 hours. Patients who received TPA and EKOS adjunct averaged
4.44 hours. The study showed no procedural mortalities and no deaths at
0 days prior to therapy. Fifty-three percent of patients had complete lysis,
7% had substantial partial lysis with freedom from supplemental oxygen. All
atients improved hemodynamically. Twelve out of 51 patients required a
lood product during their hospitalization. Nine patients required PRBC, 2
FP, and 1 with CryoPPT. There were no GI bleeds or retroperitoneal
ematomas. Long-term follow-up to 4 years showed 70% venous reflux in
he common femoral vein. Less than 20% of patients experienced a low
ncidence of recurrent deep vein thrombosis while on anti-coagulants.
Conclusions: In conclusion, aggressive thrombolysis in significant PE
s safe with substantial results within 24 hours of therapy and rapid improve-
ent in symptoms over a short duration of therapy.
